The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Benaim Ely since 2018.
This trader's CIK number is 1632237.
At the time of last reporting, Benaim Ely was the Chief Medical Officer of Novocure Ltd. (stock ticker symbol NVCR).
Also see all insider trading activities at Novocure Ltd.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | NVCR | 0 | $0 | 12,914 | $894,515 | 0 | $0 |
| 2021 | NVCR | 0 | $0 | 23,761 | $4,084,590 | 13,750 | $867,296 |
| 2020 | NVCR | 0 | $0 | 7,691 | $736,283 | 6,690 | $431,039 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2019 | RNN | 0 | $0 | 0 | $0 | 2,375 | $0 |
| 2018 | RNN | 0 | $0 | 0 | $0 | 2,375 | $0 |
2. Ocuphire Pharma, Inc. (RNN)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-08-03 | NVCR | Sale | 5,959 | 72.55 | 432,295 |
| 2022-08-02 | NVCR | Sale | 437 | 69.66 | 30,440 |
| 2022-05-10 | NVCR | Sale | 2,070 | 65.16 | 134,877 |
| 2022-05-11 | NVCR | Sale | 2,135 | 61.25 | 130,768 |
| 2022-03-03 | NVCR | Sale | 803 | 74.50 | 59,821 |
| 2022-03-04 | NVCR | Sale | 1,510 | 70.41 | 106,314 |
| 2021-08-03 | NVCR | Sale | 464 | 150.11 | 69,651 |
| 2021-08-02 | NVCR | Sale | 536 | 149.38 | 80,066 |
| 2021-07-30 | NVCR | Sale | 651 | 158.96 | 103,482 |
| 2021-07-30 | NVCR | Option Ex | 651 | 83.30 | 54,228 |
| 2021-05-27 | NVCR | Option Ex | 1,833 | 47.56 | 87,177 |
| 2021-05-27 | NVCR | Sale | 1,833 | 200.00 | 366,600 |
| 2021-05-12 | NVCR | Sale | 1,943 | 180.48 | 350,672 |
| 2021-05-10 | NVCR | Option Ex | 1,833 | 47.56 | 87,177 |
| 2021-05-10 | NVCR | Sale | 1,833 | 189.65 | 347,628 |
| 2021-05-11 | NVCR | Sale | 2,262 | 180.12 | 407,426 |
| 2021-04-13 | NVCR | Option Ex | 5,958 | 66.74 | 397,654 |
| 2021-04-13 | NVCR | Sale | 5,958 | 200.00 | 1,191,600 |
| 2021-03-05 | NVCR | Sale | 2,918 | 131.53 | 383,804 |
| 2021-03-03 | NVCR | Option Ex | 3,475 | 69.37 | 241,060 |
| 2021-03-03 | NVCR | Sale | 3,475 | 150.78 | 523,960 |
| 2021-03-04 | NVCR | Sale | 1,888 | 137.55 | 259,701 |
| 2020-12-21 | NVCR | Sale | 2,484 | 156.71 | 389,267 |
| 2020-12-21 | NVCR | Option Ex | 2,484 | 65.43 | 162,528 |
| 2020-08-03 | NVCR | Sale | 660 | 76.06 | 50,199 |
| 2020-07-31 | NVCR | Sale | 341 | 76.39 | 26,048 |
| 2020-05-12 | NVCR | Sale | 2,595 | 64.78 | 168,104 |
| 2020-05-08 | NVCR | Option Ex | 4,206 | 63.84 | 268,511 |
| 2020-05-11 | NVCR | Sale | 1,611 | 63.73 | 102,665 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-02-28 | RNN | Option Ex | 2,375 | .00 | 0 |
| 2018-02-28 | RNN | Option Ex | 2,375 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Benaim Ely (Chief Medical Officer of Novocure Ltd at the time of this reporting) see the Securities and Exchange Commission (SEC) website.